Distribution and pharmacokinetics of Photofrin® in human bile duct cancer
References (28)
- et al.
H. Lochs. Photodynamic therapy of nonresectable cholangiocarcinoma
Gastroenterology
(1998) - et al.
Biodistribution of haematoporphyrin analogues in a lung carcinoma model
Cancer Lett.
(1995) - et al.
Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid
Urology
(1994) Research into the results of resection of hilar bile duct cancer
Surgery
(1990)- et al.
Carcinoma of the extrahepatic bile ducts. Histologie types, stage of disease, grade and survival rates
Cancer
(1992) Photodynamic therapy in oncology: mechanisms and clin-ical use
J. Natl. Cancer Inst.
(1993)- et al.
Selective local control of bile duct cancer by photodynamic therapy
Gastroenterology
(1997) - et al.
Clinical pharmacokinetic studies of Photofrin by fluorescence spectroscopy in the oral cavity, the esophagus and the bronchi
Cancer
(1995) - et al.
Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse
Cancer Res.
(1981) Photodynamic therapy in gastroenterology —current status and future prospects
Endoscopy
(1993)
Tumour localisation kinetics of Photofrin, three synthetic porphyrinoids in an amelanotic melanoma of the hamster
Br. J Cancer
Evaluation of porfimer sodium fluorescence for measuring tissue transformation
Cancer
Resection or palliation: priority of surgery in the treatment of hilar cancer
World J. Surgery
Improvements in survival by aggressive resections of hilar cholangiocarcinoma
Ann. Surg.
Cited by (51)
The role of CD44 in cancer chemoresistance: A concise review
2021, European Journal of PharmacologyParallelized Monte-Carlo dosimetry using graphics processing units to model cylindrical diffusers used in photodynamic therapy: From implementation to validation
2019, Photodiagnosis and Photodynamic TherapyCitation Excerpt :The combination of these three components leads to the formation of reactive oxygen species (ROS), including singlet oxygen, which are cytotoxic molecules that damage PS-targeted cells. When using a PS with limited selectivity, light only needs to be applied on the areas to be treated (e.g., hematoporphyrin, Photofrin® [1,2]), and the organs at risk must be avoided. When using a PS with high selectivity (e.g., temoporfin, Foscan® or protoporphyrin IX (PpIX) [3–6]), the margins that are required around the targeted tumor sites can be considerably relaxed.
Statistical analysis of photodynamic therapy and stent drainage for unresectable cholangiocarcinoma
2019, Future Generation Computer SystemsRole of photodynamic therapy and intraductal radiofrequency ablation in cholangiocarcinoma
2015, Best Practice and Research: Clinical GastroenterologyCitation Excerpt :Photofrin is administered intravenously at a dose of 2 mg/kg body weight 48 h prior to the scheduled PDT. It is widely absorbed, however, more concentrated in the malignant biliary cells reaching its peak within 48 h [11]. Laser irradiation in PDT is delivered through a 3 m long quartz fiber with a 2.5–5 cm long cylindrical diffuser at the tip with an x-ray marker on both sides of the diffuser.
ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma
2014, Gastrointestinal EndoscopyCitation Excerpt :When the use of covered and uncovered metal stents was adjusted for survival time, there was no statistically significant difference in usage of either type of metal stent between these 2 groups (Table 4). Again, potential benefits of PDT include that it preferentially accumulates in malignant biliary tissue,13 which might also limit damage to the surrounding normal biliary tissue,35 and that the activating laser light can refract through bile, treating areas that are not in the direct vicinity of the laser fiber. Finally, patients in the PDT arm had significantly more follow-up ERCPs with reapplication of PDT when compared with those in the RFA arm (Table 3 [analysis unadjusted for time]), who typically underwent only 1 RFA session.
One pot synthesis of new hybrid versatile nanocarrier exhibiting efficient stability in biological environment for use in photodynamic therapy
2010, Journal of Photochemistry and Photobiology B: Biology